|Day Low/High||8.86 / 9.45|
|52 Wk Low/High||4.37 / 10.07|
Ariad Pharmaceuticals' (ARIA) stock rating was decreased to 'market perform' at JMP Securities on Tuesday.
Here are Tuesday's top research calls, including upgrades for Chesapeake Energy, McCormick and Time Warner, and a downgrade for VF Corp.
Ariad Pharmaceuticals' (ARIA) stock rating was cut to 'underweight' at JPMorgan on Monday.
Here are Monday's top research calls, including upgrades for Kinder Morgan, Verizon and 3M, and a downgrade for AT&T.
Jim Cramer says he likes LUV and UAL, but JBLU is not a favorite.
Don't ignore a big shift for American Express and don't dig in your heels, says Jim Cramer.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today acknowledged the receipt of a Congressional letter and reaffirmed its commitment to discovering and developing treatments for patients with rare cancers with the...
Senator Bernie Sanders (I-VT) and Representative Elijah Cummings (D-MD) sent a letter to Ariad Pharmaceuticals (ARIA) today questioning the company's drug pricing.
Why Trump is killing biotech stocks, the Shire-for-Radius rumor makes no sense and Bernie Sanders gets a tweeting lesson.
Do that if you like top ticking crowd favorites, but set a protective stop.
Ariad (ARIA) stock was under pressure on Friday after Bernie Sanders rebuked the company's drug pricing practices.
Cramer is avoiding TPC Composites and is lukewarm on Kinder Morgan.
Consistency and discipline are two values this market has sorely lacked in 2016, Cramer says.
Ariad Pharmaceuticals' Iclusig now costs patients nearly $199,000 per year.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
Leerink started coverage of Ariad Pharmaceuticals (ARIA) stock with an 'outperform' rating on Monday.
Ariad Pharma (ARIA) stock closed higher on Tuesday given renewed speculation that it might be a buyout target.
After putting in a bottom, Ariad Pharmaceuticals (ARIA) stock 'has risen like a Phoenix from the ashes,' said TheStreet's Chris Versace and Bob Lang.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced it has completed the rolling submission of the New Drug Application (NDA) for its investigational anaplastic lymphoma kinase (ALK) inhibitor, brigatinib, to...
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Morgan Stanley Global Healthcare Conference being held in New York City.
The company's share price despite reporting better-than-expected earnings and revenue and
ARIAD (ARIA) stock is jumping in afternoon trading today after the company reported better-than-expected results for the second quarter before Thursday's market open.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter and first half of 2016, including revenue from sales of Iclusig ® (ponatinib).
Stocks with insider trader activity include SKUL, EA and ARIA